The “4 plus 2” rituximab protocol makes maintenance treatment unneeded in patients with refractory ANCA-associated vasculitis: A 10 years observation study | Zendy

Dario Roccatello | Zendy; Savino Sciascia | Zendy; Daniela Rossi | Zendy; Mirella Alpa | Zendy; Carla Naretto | Zendy; Massimo Radin | Zendy; Roberta Fenoglio | Zendy; Simone Baldovino | Zendy; Elisa Menegatti | Zendy

Open Access

The “4 plus 2” rituximab protocol makes maintenance treatment unneeded in patients with refractory ANCA-associated vasculitis: A 10 years observation study

Author(s) -

Dario Roccatello,

Savino Sciascia,

Daniela Rossi,

Mirella Alpa,

Carla Naretto,

Massimo Radin,

Roberta Fenoglio,

Simone Baldovino,

Elisa Menegatti

Publication year - 2017

Publication title -

oncotarget

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.373

H-Index - 127

ISSN - 1949-2553

DOI - 10.18632/oncotarget.18120

Subject(s) - medicine , rituximab , granulomatosis with polyangiitis , microscopic polyangiitis , maintenance therapy , cyclophosphamide , refractory (planetary science) , gastroenterology , vasculitis , surgery , chemotherapy , disease , lymphoma , physics , astrobiology

ANCA associated vasculitides (AAV) often present with a chronic relapsing course. Relapse leads to increased immunosuppressive exposure and consequent toxicity. While two randomized controlled trials have shown rituximab (RTX) to be the most effective induction treatment in patients with relapsing disease, the optimal treatment duration and RTX dose remain debated. Whether to administer a maintenance dose to every patient, at a fixed time interval or on the basis of B cell count and ANCA titre or only when disease manifestations do occur is still debated as well.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research